JP2021522249A5 - - Google Patents
Info
- Publication number
- JP2021522249A5 JP2021522249A5 JP2020559472A JP2020559472A JP2021522249A5 JP 2021522249 A5 JP2021522249 A5 JP 2021522249A5 JP 2020559472 A JP2020559472 A JP 2020559472A JP 2020559472 A JP2020559472 A JP 2020559472A JP 2021522249 A5 JP2021522249 A5 JP 2021522249A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alkyl
- 4alkyl
- substituted
- nhs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023149057A JP7660634B2 (ja) | 2018-04-25 | 2023-09-14 | Ｎｌｒｐ３修飾因子 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662240P | 2018-04-25 | 2018-04-25 | |
| US62/662,240 | 2018-04-25 | ||
| US201862764818P | 2018-08-16 | 2018-08-16 | |
| US62/764,818 | 2018-08-16 | ||
| US201962825044P | 2019-03-28 | 2019-03-28 | |
| US62/825,044 | 2019-03-28 | ||
| PCT/US2019/028823 WO2019209896A1 (en) | 2018-04-25 | 2019-04-24 | Nlrp3 modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023149057A Division JP7660634B2 (ja) | 2018-04-25 | 2023-09-14 | Ｎｌｒｐ３修飾因子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522249A JP2021522249A (ja) | 2021-08-30 |
| JP2021522249A5 true JP2021522249A5 (OSRAM) | 2022-04-25 |
| JP7351850B2 JP7351850B2 (ja) | 2023-09-27 |
Family
ID=66677224
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559472A Active JP7351850B2 (ja) | 2018-04-25 | 2019-04-24 | Ｎｌｒｐ３修飾因子 |
| JP2023149057A Active JP7660634B2 (ja) | 2018-04-25 | 2023-09-14 | Ｎｌｒｐ３修飾因子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023149057A Active JP7660634B2 (ja) | 2018-04-25 | 2023-09-14 | Ｎｌｒｐ３修飾因子 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12037344B2 (OSRAM) |
| EP (2) | EP4353235A3 (OSRAM) |
| JP (2) | JP7351850B2 (OSRAM) |
| KR (1) | KR102711180B1 (OSRAM) |
| CN (2) | CN112521387B (OSRAM) |
| AU (1) | AU2019261582A1 (OSRAM) |
| BR (1) | BR112020021539A2 (OSRAM) |
| CA (1) | CA3097865A1 (OSRAM) |
| CL (1) | CL2020002719A1 (OSRAM) |
| CO (2) | CO2021006672A2 (OSRAM) |
| ES (1) | ES2971122T3 (OSRAM) |
| IL (1) | IL278173A (OSRAM) |
| MX (1) | MX2020011234A (OSRAM) |
| NZ (1) | NZ769136A (OSRAM) |
| PE (1) | PE20210160A1 (OSRAM) |
| SG (1) | SG11202010463TA (OSRAM) |
| TW (1) | TW202014420A (OSRAM) |
| WO (1) | WO2019209896A1 (OSRAM) |
| ZA (1) | ZA202007307B (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7573622B2 (ja) * | 2020-01-10 | 2024-10-25 | イネイト・テューマー・イミュニティ・インコーポレイテッド | Ｎｌｒｐ３モジュレーター |
| WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
| CA3179692A1 (en) * | 2020-04-16 | 2021-10-21 | Incyte Corporation | Fused tricyclic kras inhibitors |
| JP2023523756A (ja) | 2020-04-30 | 2023-06-07 | ヤンセン ファーマシューティカ エヌ．ベー． | 新規なトリアジノインドール化合物 |
| WO2021231526A1 (en) | 2020-05-13 | 2021-11-18 | Incyte Corporation | Fused pyrimidine compounds as kras inhibitors |
| CA3177672A1 (en) * | 2020-05-28 | 2021-12-02 | Michael Eric MURATORE | Compounds |
| CN116390923B (zh) * | 2020-08-21 | 2025-08-29 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和用途 |
| US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
| WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
| EP3984535A1 (en) * | 2020-10-16 | 2022-04-20 | Albert-Ludwigs-Universität Freiburg | Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome |
| US20240101570A1 (en) * | 2020-11-24 | 2024-03-28 | Amgen Inc. | Tricyclic carboxamide derivatives as prmt5 inhibitors |
| CN114539095A (zh) * | 2020-11-26 | 2022-05-27 | 乐凯化学材料有限公司 | 3-（4-羟基-3-甲氧基-苯基）-2-氰基-2-丙烯酸乙酯的制备方法 |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| AU2022306671A1 (en) | 2021-07-07 | 2024-01-25 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| JP2024529347A (ja) | 2021-07-14 | 2024-08-06 | インサイト・コーポレイション | Ｋｒａｓの阻害剤としての三環式化合物 |
| US20240254132A1 (en) * | 2021-07-16 | 2024-08-01 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| JP2024534187A (ja) | 2021-08-31 | 2024-09-18 | インサイト・コーポレイション | Ｋｒａｓの阻害剤としてのナフチリジン化合物 |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| EP4408536A1 (en) | 2021-10-01 | 2024-08-07 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
| KR20240101561A (ko) | 2021-10-14 | 2024-07-02 | 인사이트 코포레이션 | Kras의 저해제로서의 퀴놀린 화합물 |
| WO2025190317A1 (en) * | 2024-03-13 | 2025-09-18 | National Institute Of Biological Sciences, Beijing | Urea compounds as nlrp3 agonists |
| WO2026006603A1 (en) * | 2024-06-26 | 2026-01-02 | Wisconsin Alumni Research Foundation | Tlr7/tlr8 agonists for use in trifunctional radiopharmaceutical compounds |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110929A (en) * | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| HRP20130077A2 (hr) | 1998-12-23 | 2013-07-31 | Pfizer Inc. | Humana monoklonalna protutjela za ctla-4 |
| CN102766210B (zh) | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US20090075980A1 (en) | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
| KR101494056B1 (ko) | 2003-10-03 | 2015-02-16 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 피라졸로피리딘 및 그의 유사체 |
| US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| WO2006093514A2 (en) * | 2004-06-18 | 2006-09-08 | 3M Innovative Properties Company | Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines |
| US20080193468A1 (en) * | 2004-09-08 | 2008-08-14 | Children's Medical Center Corporation | Method for Stimulating the Immune Response of Newborns |
| CA2602083A1 (en) | 2005-02-09 | 2006-08-09 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| CN101784547A (zh) | 2007-08-14 | 2010-07-21 | 诺瓦提斯公司 | 作为GABAα配体的吡唑并喹啉和吡唑并萘啶衍生物 |
| EP2303890A4 (en) | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| NO2504364T3 (OSRAM) | 2009-11-24 | 2018-01-06 | ||
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112013026744B1 (pt) * | 2011-04-21 | 2022-05-17 | Origenis Gmbh | Compostos heterocíclicos, seus usos e seus intermediários, e composição farmacêutica |
| ES2527188T3 (es) | 2011-09-26 | 2015-01-21 | Sanofi | Derivados de pirazolquinolinona, su preparación y su uso terapéutico |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| AU2013263076B2 (en) | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| AU2013267161A1 (en) | 2012-05-31 | 2014-11-20 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| ME03586B (me) | 2013-05-18 | 2020-07-20 | Univ California | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od .,stimulatora gena za interferon" |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| CN104418867B (zh) * | 2013-08-26 | 2016-12-28 | 上海汇伦生命科技有限公司 | 作为PI3K/mTOR抑制剂的化合物，其制备方法和用途 |
| LT3702373T (lt) | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| WO2015095780A1 (en) | 2013-12-20 | 2015-06-25 | The University Of Kansas | Toll-like receptor 8 agonists |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| CN112546230A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CA2954446A1 (en) | 2014-07-09 | 2016-01-14 | Shanghai Birdie Biotech, Inc. | Anti-pd-l1 combinations for treating tumors |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CA2986765A1 (en) | 2015-05-29 | 2016-12-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| WO2016199943A1 (en) | 2015-06-11 | 2016-12-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| EP3344262A4 (en) | 2015-09-01 | 2019-03-20 | Innate Tumor Immunity, Inc. | IMMUNOCELLS WITH INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE THEREOF |
| EP3344656A1 (en) | 2015-09-01 | 2018-07-11 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| CN105523955B (zh) * | 2015-12-14 | 2018-08-17 | 北京嘉林药业股份有限公司 | 化合物及其在制备药物中的用途 |
| CN115554406A (zh) | 2016-01-07 | 2023-01-03 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| CN111385767A (zh) | 2016-02-02 | 2020-07-07 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
| BR112018071347A2 (pt) | 2016-04-19 | 2019-02-05 | Innate Tumor Immunity Inc | moduladores de nlrp3 |
| US10533007B2 (en) | 2016-04-19 | 2020-01-14 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| US11344543B2 (en) | 2017-07-14 | 2022-05-31 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| SG11202010068VA (en) | 2018-04-25 | 2020-11-27 | Bayer Ag | Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides |
-
2019
- 2019-04-24 CN CN202011468364.4A patent/CN112521387B/zh active Active
- 2019-04-24 KR KR1020207033384A patent/KR102711180B1/ko active Active
- 2019-04-24 WO PCT/US2019/028823 patent/WO2019209896A1/en not_active Ceased
- 2019-04-24 EP EP23211253.2A patent/EP4353235A3/en active Pending
- 2019-04-24 MX MX2020011234A patent/MX2020011234A/es unknown
- 2019-04-24 CA CA3097865A patent/CA3097865A1/en active Pending
- 2019-04-24 EP EP19727780.9A patent/EP3784670B1/en active Active
- 2019-04-24 JP JP2020559472A patent/JP7351850B2/ja active Active
- 2019-04-24 ES ES19727780T patent/ES2971122T3/es active Active
- 2019-04-24 AU AU2019261582A patent/AU2019261582A1/en not_active Abandoned
- 2019-04-24 CN CN201980027881.7A patent/CN112074516A/zh active Pending
- 2019-04-24 NZ NZ769136A patent/NZ769136A/en unknown
- 2019-04-24 PE PE2020001652A patent/PE20210160A1/es unknown
- 2019-04-24 BR BR112020021539-2A patent/BR112020021539A2/pt not_active IP Right Cessation
- 2019-04-24 US US17/049,612 patent/US12037344B2/en active Active
- 2019-04-24 SG SG11202010463TA patent/SG11202010463TA/en unknown
- 2019-04-25 TW TW108114491A patent/TW202014420A/zh unknown
-
2020
- 2020-10-20 IL IL278173A patent/IL278173A/en unknown
- 2020-10-21 CL CL2020002719A patent/CL2020002719A1/es unknown
- 2020-10-21 CO CONC2021/0006672A patent/CO2021006672A2/es unknown
- 2020-10-21 CO CONC2020/0013155A patent/CO2020013155A2/es unknown
- 2020-11-24 ZA ZA2020/07307A patent/ZA202007307B/en unknown
-
2023
- 2023-09-14 JP JP2023149057A patent/JP7660634B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534168A5 (OSRAM) | ||
| JP2021534158A5 (OSRAM) | ||
| JP2020125349A5 (OSRAM) | ||
| JP2018510191A5 (OSRAM) | ||
| JP2020508302A5 (OSRAM) | ||
| JP2022517109A5 (OSRAM) | ||
| JP2023541522A5 (OSRAM) | ||
| RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
| JP2020097596A5 (OSRAM) | ||
| JP2022501327A5 (OSRAM) | ||
| JP2020504716A5 (OSRAM) | ||
| JP2023506787A5 (OSRAM) | ||
| JP2015536986A5 (OSRAM) | ||
| WO2007143483A2 (en) | Combination of pazopanib and lapatinib for treating cancer | |
| JP2022517110A5 (OSRAM) | ||
| JP2018062523A5 (OSRAM) | ||
| AU2015301097A1 (en) | Drug combinations to treat multiple myeloma | |
| RU2014141934A (ru) | Комбинация производного 6-оксо-1,6-дигидро-пиридазина, которая обладает противораковым действием с другими противоопухолевыми соединениями | |
| RU2013143520A (ru) | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний | |
| JP2020506884A5 (OSRAM) | ||
| JP2024542633A5 (OSRAM) | ||
| JP2019522681A5 (OSRAM) | ||
| RU2017124371A (ru) | Комбинация производного 6-оксо-1,6-дигидро-пиридазина, обладающего противораковой активностью, с производным хиназолина | |
| BR112021015908A2 (pt) | Composição antitumoral | |
| US20090005406A1 (en) | Cancer Treatment Method |